Clinical Trials Directory
Recruiting
Conditions
Sponsors
Search
About
Trials
/
Sponsors
/ Ophthotech Corporation
Ophthotech Corporation
Industry · 13 registered clinical trials.
Status
Trial
Phase
Started
Withdrawn
ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
Idiopathic Polypoidal Choroidal Vasculopathy
Phase 2
2018-11-01
Completed
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
Neovascular Age-related Macular Degeneration
Phase 2
2017-10-11
Terminated
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Adminis
Age-Related Macular Degeneration
Phase 2
2016-04-26
Completed
A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Th
Idiopathic Polypoidal Choroidal Vasculopathy
Phase 2
2015-03-12
Terminated
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF
Age-related Macular Degeneration
Phase 2
2014-07-01
Terminated
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Eith
Age-Related Macular Degeneration
Phase 3
2014-05-01
Terminated
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Luce
Age-Related Macular Degeneration
Phase 3
2013-08-01
Terminated
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Luce
Age-Related Macular Degeneration
Phase 3
2013-08-01
Completed
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related
Age-Related Macular Degeneration
Phase 2
2010-03-01
Completed
A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
Dry Age-Related Macular Degeneration
Phase 1
2009-07-16
Completed
ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degenerati
Neovascular Age-Related Macular Degeneration
Phase 1
2008-10-16
Completed
A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profil
Age-related Macular Degeneration
Phase 1
2008-10-01
Completed
A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF P
Age-related Macular Degeneration
Phase 1
2007-12-01